CCM
AERI

Consonance Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History

Consonance Capital Management’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,506,695
Closed -$44.5M – 37
2019
Q2 		$44.5M Sell
1,506,695
-190,078
-11% -$7.32M 3.15% 13
2019
Q1 		$80.6M Buy
+1,696,773
New +$74.7M 5.09% 8

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Consonance Capital Management's AERI Position: Q3 2019 in Review

Consonance Capital Management sold out of Aerie Pharmaceuticals (AERI) in Q3 2019, closing a stake of 1,506,695 shares — an estimated $44.5M sold.

Consonance Capital Management first reported a position in AERI in Q1 2019 and held it in 2 quarters. The position peaked at $80.6M in Q1 2019. 167 funds tracked by Wall St. Rank hold AERI as of Q3 2019.

  • Consonance Capital Management reported no remaining Aerie Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Consonance Capital Management sold 1,506,695 Aerie Pharmaceuticals shares in Q3 2019, an estimated $44.5M.
  • Consonance Capital Management first reported a position in Aerie Pharmaceuticals in Q1 2019 and held it in 2 quarters.
  • Consonance Capital Management's Aerie Pharmaceuticals position peaked at $80.6M in Q1 2019.
  • 167 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2019.

Based on Consonance Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.